INTRODUCTION
It has been 5 years since the first mammalian Toll-like receptor, now known as human TLR4, was cloned. 1 Since that time, a great deal of interest has focused on the capacity of the different TLRs to act as 'pattern recognition receptors' for structurally diverse microbial structures, suggesting that TLRs evolved to enable the host to detect and respond to different pathogens. Until recently, the 'core' paradigm for TLR signaling might have been summarized as follows: TLR2 or TLR4, like the IL-1 and IL-18 receptors, recruits the adaptor molecule, MyD88, which initiates a sequential cascade of protein-protein interactions that results in NF-kB translocation and culminates in the expression of NF-kB-responsive genes (reviewed by O'Neill & Greene 2 ). However, at the 2000 IES meeting, we presented data that would not be predicted by this simplistic model: the TLR4 agonist, Escherichia coli LPS, strongly induced a large number of inflammatory genes in murine macrophages, while the TLR2 agonist, Pseudomonas gingivalis LPS, induced some genes rather comparably, while the steady-state levels of others were either less sustained over time or were not inducible. 3, 4 Jones et al. 5 reported similar findings with respect to the differential induction of the inducible nitric oxide synthase (iNOS) gene and nitric oxide release by mycobacterial TLR4 versus TLR2 agonists. Two subsequent publications showing similar patterns of differential gene expression in response to TLR2 and TLR4 agonists in dendritic cells followed soon thereafter. 6, 7 This led us to hypothesize that differences in the repertoires of genes induced by TLR4 versus TLR2 agonists reflected differential utilization of signaling pathways apart from that which led to the translocation of NF-kB.
That TLRs share a common MyD88-dependent signaling pathway which results in the generation of nuclear DNA-binding proteins, such as NF-kB, is a well-accepted paradigm. However, studies from our laboratories and others suggested that TLR4 agonists elicit a more diverse pattern of gene expression in murine macrophages than TLR2 agonists. The data presented show that activation of TLR4 by Escherichia coli LPS results in an MyD88-independent, TIRAP/Mal-dependent signaling pathway that, in turn, leads to early induction of interferon-b (IFN-b). IFN-b, in turn, acts in an autocrine/paracrine fashion on the macrophage to activate STAT1-containing DNA binding complexes that participate in the induction of genes not expressed in response to natural or synthetic TLR2 agonists. These data support the hypothesis that the host response to microbes is controlled by TLRs at two levels: (i) the 'sensing' of differences in microbial structures through the TLR extracellular domain; and (ii) signaling pathways that are initiated via interactions through unique intracytoplasmic regions of different TLRs with adaptor proteins.
We now know much more about the signaling induced by TLRs. Indeed, at the 2000 IES meeting, Akira presented data showing that macrophages derived from MyD88 knockout mice exhibited residual NF-kB translocation and ERK phosphorylation, 8, 9 which led to the discovery of a second adaptor molecule, called TIRAP by Horng et al. 10 or Mal by Fitzgerald et al. 11 Collectively, these latter two reports showed that TIRAP/Mal binds to a site on the intracytoplasmic portion of TLR4 that is distinct from MyD88, yet co-immunoprecipitation experiments indicate that TIRAP/Mal interacts with MyD88. Inhibition of TIRAP/Mal also blocked MyD88 signaling. Horng et al. showed that one downstream target of TIRAP was the double-stranded RNAdependent protein kinase, PKR. TIRAP/Mal expression was not necessary for IL-1-, IL-18-, or TLR9-mediated signaling as evidenced by a failure of TIRAP/Mal inhibition to alter signaling by agonists for these receptors, while TLR4induced signaling was blocked; however, the role of TIRAP/Mal in TLR2 signaling was not explored. 10, 11 The purpose of these studies was to confirm and extend our previous analysis of the capacity of P. gingivalis LPS to induce a subset of genes induced by E. coli LPS with a synthetic TLR2 agonist, Pam3Cys, and to identify novel signaling pathways in this process. Our findings show that TLR4 agonists, but not TLR2 agonists, induce early expression of IFN-b mRNA and protein, and that this acts on the macrophage to initiate STAT1 signaling. Activated STAT1, in turn, contributes to the expression of a subset of inflammatory genes not induced by TLR2 agonists. Both STAT1 activation and IFN-b induction were found to be MyD88-and PKR-independent, but TIRAP/Mal-dependent. IRAK-1-associated kinase activity is also differentially induced by TLR4 versus TLR2 agonists.
MATERIALS AND METHODS

Sources of macrophages
The murine macrophage cell line, RAW 264.7, was obtained from the American Type Culture Collection (Manassas, VA, USA). Primary murine peritoneal macrophages were elicited by injection of mice with sterile thioglycollate. The sources of the mouse strains used in this study and the details of macrophage culture have been described elsewhere. 12 
Reagents
All reagents used in this study have been described previously. 12 The synthetic lipopeptide, S-[2,3-bis(palmitoxyloxy)-(2-RS)-propyl]-N-palmitoyl-(R)-Cys-(S)-Ser-Lys4-OH (Pam3Cys) was originally obtained from EMC Microcollections GmbH (Tübingen, Germany); more recently, this reagent was purchased from Prof. Dr Guenther Jung, Institute of Organic Chemistry, University of Tübingen.
Measurements of steady-state mRNA
Methods for detection of specific mRNA species by RT-PCR and either Southern blot analysis or ethidium bromide uptake have been described previously. 12 
Transfection and reporter assays
The human IFN-b promoter luciferase reporter construct, PGL-3-IFN-b-Luc, was the kind gift of J. Hiscott and R. Lin (McGill University, Montreal, Canada). The TIRAP-DN mutant plasmid was kindly provided by R. Medzhitov and was described by Horng et al. 10 All transient transfections were carried out in the RAW 264.7 cell line as described elsewhere. 12 
IRAK-1 kinase assay
IRAK-1 kinase activity was measured in macrophage cell lysates as described by Li et al. 13 Briefly, macrophages were stimulated with LPS or Pam3Cys and were lysed at the times indicated. Lysates were subjected to immunoprecipitation using anti-IRAK-1-specific antibody (Upstate Biotechnology Inc.) as described. IRAK-1-containing immunoprecipitates were exposed to [ 32 P]-ATP and myelin basic protein (MBP) as a substrate, and were subjected to gel electrophoresis. Radioactivity was measured using a phosphorimager.
Detection of phospho-eIF2a and total eIF2a by immunoblot analysis
After treatment with agonists, cells were lysed in lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 50 mM NaF, 10 mM b-glycerophosphate, 0.1 mM EDTA, 10% glycerol, 1% Triton X-100) supplemented with protease/phosphatase inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate, 2 mg/ml of each leupeptin, aprotinin and leupeptin), followed by incubation on ice for 20 min. Lysates were centrifuged at 14,000 g for 20 min, and the supernatant was collected. Proteins were quantified by Bradford assays. Cell lysates (30 mg) were resolved by 10% SDS-PAGE, transferred to polyvinylidene difluoride membranes (Immobilon-P, Millipore), and probed with the antibodies as indicated. Immunoblotting with phospho-eIF2a(Ser51) antibody (Cell Signaling) was performed as recommended by the manufacturer. Immunoblotting with anti-eIF2a antibody (FL-315; Santa Cruz Biotechnology, Inc.) was performed as follows. Filters were blocked with 5% non-fat milk/TBS-Tween 0.1% (TBS-T) at room temperature for 1 h. After three washings in TBS-T for 5 min each, filters were incubated with anti-eIF2 antibody prediluted 1:500 in 5% non-fat milk/TBS-T, and kept under moderate agitation for 16 h at 40°C. Filters were washed 3 times with TBS-T for 5 min each before and after incubation with the anti-rabbit horseradish peroxidase-conjugated secondary antibody (1:2000 diluted in 5% non-fat milk/TBS-T) for 1 h at room temperature. Proteins were detected by using enhanced chemiluminescence (ECL) according to the manufacturer's recommendations (Amersham).
RESULTS
Previous studies found that TLR2 agonists induced a subset of genes that are induced by TLR4 agonists, but fail to express a number of pro-inflammatory genes including the chemokine genes, MCP-5 and IP-10, 4 and iNOS mRNA. 5 Therefore, we sought to confirm our findings with a synthetic TLR2 agonist, Pam3Cys, as well as with higher concentra-tions of the P. gingivalis LPS than used in the initial studies. Figure 1 illustrates that both the synthetic and natural TLR2 agonists elicited fairly equivalent levels of TNF-a and IL-1b mRNA, yet they induced MCP-5, IP-10, and iNOS very poorly compared to the TLR4 agonist. The concentrations of Pam3Cys and P. gingivalis LPS used in this experiment were 10-100 times more than required to induce IL-1b or TNF-a mRNA or phosphorylation of the mitogen-activated protein kinases, p38, JNK-1/2, or ERK-1/2. 12 Gao et al. 14 showed that LPS-induced iNOS gene expression was dependent on the DNA-binding protein, activated STAT1. Kopydlowski et al. 15 and Ohmori and Hamilton 16 further demonstrated macrophages from STAT1 knockout mice to be defective in their ability to respond to LPS to express IP-10, MCP-5, as well as iNOS mRNA. Therefore, we hypothesized that TLR4, but not TLR2, agonists would induce STAT1 phosphorylation. Figure 2A illustrates that E. coli LPS, but not Pam3Cys, induces phosphorylation of STAT1 on tyrosine. This induction of STAT1 phosphorylation by LPS required TLR4 signaling since C3H/HeJ macrophages failed to exhibit STAT1 phosphorylation in response to E. coli LPS. A number of other TLR2 agonists, including the P. gingivalis LPS, soluble tuberculosis factor (STF), lipoarabinomannan (LAM), and dimannosylated TLR2 and TLR4 agonists stimulate unique repertoires of host resistance genes in macrophages 171 phosphatidylinositol (PIM), all failed to induce STAT1 phosphorylation (data not shown). 12 Even at concentrations 10-100-fold more than required to elicit TNF-a or IL-1b gene expression, neither the Pam3Cys nor the P. gingivalis LPS induced STAT1 phosphorylation. 12 Consistent with the findings of Gao et al., 14 induction of STAT1 phosphorylation by E. coli LPS was delayed when compared to IFN-g (i.e. ~2-3 h versus < 30 min), suggesting the possibility that STAT1 phosphorylation required de novo protein synthesis. This hypothesis was borne out by the data shown in Figure 2B . The presence of the protein synthesis inhibitor, cycloheximide (CHX), blocked LPS-induced STAT1 phosphorylation. Thus, the failure to activate the STAT1 signaling pathway distinguishes TLR2 agonists from TLR4 agonists.
Gao et al. 14 also previously showed that a polyclonal antibody to type I IFNs would block LPS-induced STAT1 phosphorylation. We confirmed and extended these findings using monoclonal antibodies specific for either IFN-a or IFN-b, and found that only the anti-IFN-b blocked STAT1 phosphorylation (data not shown). 12 This led to the hypothesis that IFN-b was the necessary intermediate for STAT1 activation by LPS and that IFN-b mRNA would be induced differentially by TLR4 versus TLR2 agonists. Indeed, under conditions where these three agonists all induced comparable levels of TNF-a mRNA (Fig. 1) , only the TLR4 agonist induced IFN-b mRNA (Fig. 3 ). Figure 3 also shows that IFN-b is one of the very earliest genes induced by LPS, peaking at 1 h of stimulation of macrophages. By overcycling during RT-PCR, one can detect faint induction of IFN-b mRNA by the TLR2 agonists, but this is considerably less and more transient than seen in response to E. coli LPS. That IFN-g is not contributing to the activation of STAT1 by LPS is supported by two findings. First, induction of IFN-g mRNA is seen several hours after IFN-b mRNA is induced and peak STAT1 activation is observed (Fig. 3) . Secondly, macrophages from IFN-g knockout mice responded to this same preparation of LPS with STAT1 phosphorylation. 14 Differential induction of a human IFN-b promoter luciferase reporter construct in transiently transfected RAW 264.7 macrophages stimulated by E. coli LPS or another TLR2 agonist, araLAM, confirmed our findings in primary macrophages (Fig. 4) .
To dissect the role of the various signaling intermediates in the induction of IFN-b gene expression by LPS, we first utilized macrophages derived from MyD88 wild-type and knockout mice and found that induction of both STAT1 phosphorylation and IFN-b gene expression were MyD88-independent (data not shown). 12 Using the human IFN-b promoter luciferase reporter construct, we also tested the dependency on TIRAP/Mal using a TIRAP DN construct that was first employed in the study by Horng et al. 10 Under conditions where the reporter expression induced by LPS was significantly inhibited (82%), the reporter activity induced by CpG DNA, a TLR9 agonist, was not (6.7%). This finding was confirmed using a TIRAP inhibitory peptide 10 to inhibit LPS-induced endogenous IFN-b gene expression, but not CpG-induced gene expression (data not shown). 12 After MyD88 binds to TLRs, IRAK is recruited (reviewed by O'Neill & Green 2 ). Interestingly, Fitzgerald et al. 11 reported that IRAK-1 was found to associate preferentially with MyD88, not TIRAP. However, IRAK-1 kinase activity, as assessed by phosphorylation of the substrate myelin basic protein, is preferentially activated in macrophages stimulated with the TLR4 agonist ( Fig. 5 ).
PKR is a kinase that was reported to be a downstream target of LPS-activated TIRAP/Mal. 10 We previously reported that PKR knockout macrophages respond normally to LPS to induce IFN-b as well as the STAT1-dependent genes, IP-10, MCP-5, and iNOS. 12 Figure 6 extends these findings by showing that phosphorylation of the endogenous substrate of PKR, eIF2a, by TLR4 versus TLR2 agonists was fairly comparable (top panel). Western blot analysis for total eIF2a was included as a control for protein loading. Therefore, PKR is not necessary for the LPS-induced IFN-b-mediated gene expression.
TLR2 and TLR4 agonists stimulate unique repertoires of host resistance genes in macrophages 173 5 . Preferential activation of IRAK-1 kinase activity by TLR4 versus TLR2 agonists. RAW 264.7 cells were treated for the indicated times with E. coli LPS or Pam3Cys, the cells were lysed and IRAK-1 kinase activity measured as described in Materials and Methods. P-MBP, phosphorylated myelin basic protein. 
DISCUSSION
In summary, the model shown in Figure 7 demonstrates that TLR4 signaling can be distinguished from TLR2 signaling by its ability to induce IFN-b through a pathway that is MyD88-independent, yet inhibited by the identical TIRAP DN construct and TIRAP inhibitory peptide that were used to describe this second adaptor. 10 The induction of the pathway leading to IFN-b mRNA expression is also independent of PKR, which was reported to be a downstream target of TIRAP. 10 IFN-b can then interact with the macrophage through its specific receptor (IFNABR) to initiate STAT1 tyrosine phosphorylation that is necessary for generation of STAT1-containing, DNA binding complexes that are required for expression of genes such as IP-10, MCP-5, and iNOS. Recent studies have implicated IRF-3 as an early inducer of IFN-b [17] [18] [19] [20] and, therefore, we have put it upstream of IFN-b mRNA induction in the model. Further studies to identify the upstream kinase for IRF-3 and its possible role in LPS-induced IFN-b will be necessary to understand this pathway more completely. The failure of TLR2 agonists to elicit induction of IFN-b mRNA does not preclude a role for TIRAP in TLR2 signaling; however, TIRAP has only been shown to be constitutively associated with TLR4. 11 Moreover, additional TIRAP/Mal-dependent, but IFN-b-independent, immediate early gene expression has been found, 21 indicating that additional signaling bifurcations from TIRAP/Mal exist, perhaps suggesting the existence of additional adaptor molecules. Continued analysis of such differences may provide novel targets for therapeutic intervention. 
